Ocular Drug Delivery Devices Market Size & Share, by Type (Topical, Iontophoresis, Ocular Insert, Intraocular Implants, In-situ Gel); Drug Form (Solution, Suspension, Emulsion, & Others); Disease Type (Glaucoma, Diabetic Macular Edema, Diabetic Retinopathy, Macular Degeneration, Cataract, Refractive Issues); End-user (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, Homecare Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 4029
Published Date: Apr 20, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Ocular Drug Delivery Devices Landscape

Bausch Health Companies Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Taiwan Liposome Company, Ltd.
Ocular Therapeutix, Inc.
Kiora Pharmaceuticals, Inc.
Graybug Vision Inc.
Apellis Pharmaceuticals, Inc.
Implanet Company
Aerie Pharmaceuticals Inc.
EyePoint Pharmaceuticals, Inc.
Protalix BioTherapeutics

Browse Key Market Insights with Data Illustration:

Ocular Drug Delivery Devices Market Size Report - 2035

In the News

EyePoint Pharmaceuticals, Inc. announced the interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD.
EyeGate Pharmaceuticals, Inc. announced the first successful dosage of its drug PP-001 in the phase II proof-of-concept (“POC”) study of ocular surface inflammation. PP-001 is an inhibitor of dihydroorotate dehydrogenase

Frequently Asked Questions (FAQ)

Increasing prevalence of ocular diseases and growing awareness amongst people regarding vision impairment are estimated to boost the market growth

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

High competition from generic products and discomfort such as irritation and excessive lachrymation is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Bausch Health Companies Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Kiora Pharmaceuticals, Inc., Graybug Vision Inc., Apellis Pharmaceuticals, Inc., Implanet Company, and Aerie Pharmaceuticals Inc. EyePoint Pharmaceuticals, Inc., Protalix BioTherapeutics.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, drug type, disease type, end-user, and by region.

The ophthalmic clinics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Companies Dominating the Ocular Drug Delivery Devices Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the ocular drug delivery devices market?

What would be the CAGR of ocular drug delivery devices market over the forecast period?

What are the challenges affecting the ocular drug delivery devices market growth?

Which region will provide more business opportunities for growth of ocular drug delivery devices market in future?

Who are the major players dominating the ocular drug delivery devices market?

How are the company profiles selected?

What are the segments in the ocular drug delivery devices market?

Which segment captures the largest market size in end-user segment in the ocular drug delivery devices market?